Cite
Wailoo AJ, Stevenson M, Tosh J, et al. The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards. Value Health. 2014;17(7):A380doi: 10.1016/j.jval.2014.08.2611.
Wailoo, A. J., Stevenson, M., Tosh, J., Hernández, M., Stevens, J. W., Archer, R., Simpson, E., Everson, H. E., Scott, D., Young, A., Paisley, S., & Williams, K. (2014). The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A380. https://doi.org/10.1016/j.jval.2014.08.2611
Wailoo, A J, et al. "The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A380. doi: https://doi.org/10.1016/j.jval.2014.08.2611
Wailoo AJ, Stevenson M, Tosh J, Hernández M, Stevens JW, Archer R, Simpson E, Everson HE, Scott D, Young A, Paisley S, Williams K. The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards. Value Health. 2014 Nov;17(7):A380. doi: 10.1016/j.jval.2014.08.2611. Epub 2014 Oct 26. PMID: 27200840.
Copy
Download .nbib